Bristol Myers Squibb announced results from the Phase 3 CheckMate -651 trial comparing Opdivo (nivolumab) plus Yervoy (ipilimumab) to the EXTREME regimen (cetuximab, cisplatin/carboplatin and fluorouracil) as a first-line…
The Cancer Research Institute (CRI), a U.S. nonprofit organization dedicated to saving more lives through the discovery and development of powerful immunotherapies for all cancers,…
An African American principal investigator, Tarsha Jones, PhD recently received a five-year, $772,525 Career Development Award from the National Institutes of Health (NIH) K01 Career…
TrialSite has written extensively about the importance of clinical research as a care option, especially in therapeutic areas such as oncology where the standard of…
Rain Therapeutics Inc., a clinical-stage company developing precision oncology therapeutics, today announced that the first patient has been randomized in the multicenter, open-label, Phase 3…
In a deal worth nearly $1 billion if all milestones are met, one of the world’s largest biotech companies, Cambridge, MA-based Biogen Inc. (Nasdaq: BIIB) licensed…
ALX Oncology presented updated clinical data from its ongoing ASPEN-01 trial evaluating ALX148 in combination with trastuzumab and chemotherapy for the treatment of gastric or…
Lung cancer survivors face a myriad of challenges, including severe neuropathic pain such as numbness, tingling pins-and-needles type sensations, sensitivity to touch as well as…
Three oncology practices with a combined total of ten physicians have recently joined The Center for Cancer and Blood Disorders (The Center), the growing North…
The Princess Máxima Center inked a Memorandum of Understanding (MOU) indicating a deal with the Hopp Children’s Cancer Center Heidelberg (KiTZ), the German Cancer Research…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
